Europska Unija - hrvatski - EMA (European Medicines Agency)

bausch + lomb ireland limited - bromfenak natrij seskvihidrat - pain, postoperative; ophthalmologic surgical procedures - ophthalmologicals - liječenje postoperativne očne upale nakon ekstrakcije katarakta kod odraslih osoba.

Europska Unija - hrvatski - EMA (European Medicines Agency)

n.v. organon - alendronic kiseline, colecalciferol - osteoporoza, postmenopauzalna - lijekovi za liječenje bolesti kostiju - liječenje osteoporoze u postmenopauzi u bolesnika s rizikom od insuficijencije vitamina d. vantavo smanjuje rizik od prijeloma kralježnice i kukova . liječenje постменопаузального osteoporoze kod bolesnika koji ne primaju vitamina d prehrani i rizika vitamina d bubrega. vantavo smanjuje rizik od prijeloma kralježnice i kukova .

Europska Unija - hrvatski - EMA (European Medicines Agency)

viiv healthcare b.v. - dolutegravir sodium, lamivudine, abacavir (as sulfate) - hiv infekcije - antivirusni lijekovi za sustavnu uporabu - triumeq is indicated for the treatment of human immunodeficiency virus (hiv) infected adults,  adolescents and children  weighing at least 25 kg who are antiretroviral treatment-naïve or are infected with hiv without documented or clinically suspected resistance to any of the three antiretroviral agents in triumeq.

Europska Unija - hrvatski - EMA (European Medicines Agency)

cis bio international - samarium (153sm) lexidronam pentasodium - pain; cancer - terapeutski radiofarmaceutski pripravci - quadramet je indiciran za olakšanje koštana bol u bolesnika s više bolno u tu svrhu koštanih metastaza koje zauzimaju tehnecij [99mtc]-s natpisom biphosphonates na kost skeniranja. dostupnost остеобластические metastaza, koje zauzimaju технеция [99мтс]-za označene biphosphonates mora biti potvrđena prije početka terapije.

Europska Unija - hrvatski - EMA (European Medicines Agency)

ucb pharma ltd - natrij oksibat - cataplexy; narcolepsy - ostali lijekovi protiv živčanog sustava - liječenje narkolepsije s cataplexy u odraslih bolesnika.

Europska Unija - hrvatski - EMA (European Medicines Agency)

alnylam netherlands b.v. - lumasiran sodium - hyperoxaluria, primary - drugi gastrointestinalni trakt i metabolizam, lijekovi, - treatment of primary hyperoxaluria type 1 (ph1) in all age groups.

Europska Unija - hrvatski - EMA (European Medicines Agency)

alnylam netherlands b.v. - vutrisiran sodium - amyloid neuropathies, familial - ostali lijekovi protiv živčanog sustava - treatment of hereditary transthyretin-mediated amyloidosis (hattr amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.

Europska Unija - hrvatski - EMA (European Medicines Agency)

orion corporation - l-dopa, карбидопа, энтакапон - parkinsonova bolest - antiparkinsonski lijekovi - corbilta je indicirana za liječenje odraslih pacijenata s parkinsonovom bolešću i motoričkim promjenama na kraju doza, koji nisu stabilizirani na liječenju inhibitorima levodopa / dopa dekarboksilaze (ddc).

Europska Unija - hrvatski - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - empagliflozin - diabetes mellitus, type 2; heart failure; renal insufficiency, chronic - lijekovi koji se koriste u dijabetesu - type 2 diabetes mellitusjardiance is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered in addition to other medicinal products for the treatment of diabetesfor study results with respect to combinations of therapies, effects on glycaemic control, and cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 i 5. of the annex. heart failurejardiance is indicated in adults for the treatment of symptomatic chronic heart failure.  chronic kidney diseasejardiance is indicated in adults for the treatment of chronic kidney disease.

Europska Unija - hrvatski - EMA (European Medicines Agency)

eli lilly nederland b.v. - dulaglutide - dijabetes mellitus, tip 2 - drugs used in diabetes, blood glucose lowering drugs, excl. insulins - trulicity is indicated for the treatment of patients 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes. prema rezultatima istraživanja u vezi kombinacije, utjecaj na glikemijski kontrolu i kardiovaskularnih događaja, a u ispitivanih skupina, vidi 4. 4, 4. 5 i 5.